Crown Laboratories, a privately held, fully integrated global skin care company, has acquired North American distribution rights of five OTC consumer brands from GlaxoSmithKline (GSK).
British drugmaker GlaxoSmithKline (GSK) has entered into a collaboration with Kyowa Hakko Kirin to commercialize daprodustat in Japan.
Life sciences company Cambrex has agreed to acquire Avista Pharma Solutions, a North Carolina-based contract development, manufacturing, and testing organization, for about $252m.
Nexus Pharmaceuticals has announced the immediate availability of Arsenic Trioxide Injection in 10mg per 10mL vial in the US.
AstraZeneca has agreed to offload the US rights of its respiratory drug Synagis (palivizumab) to Swedish Orphan Biovitrum (Sobi) in a cash-cum-stock deal worth $1.5bn.
Ferring Pharmaceuticals has announced the US launch of NOCDURNA (desmopressin acetate), a sublingual tablet indicated for the treatment of nocturia due to nocturnal polyuria (NP) in adults who awaken more than two times per night to void.
AstraZeneca has agreed to offload its rights to asthma drug Alvesco (ciclesonide) and nasal sprays Omnaris and Zetonna (ciclesonide) to Covis Pharma for $350m.
Quotient Sciences, a global pharmaceutical development, clinical pharmacology and clinical and commercial manufacturing organization, has significantly expanded its formulation development and clinical trial manufacturing operations at its Reading facility, UK.
Janssen Pharmaceuticals is voluntary recalling one lot of Ortho-Novum 1/35 (norethindrone/ethinyl estradiol) tablets and two lots of Ortho-Novum 7/7/7 (norethindrone/ethinyl estradiol) tablets to the pharmacy level.
GW Pharmaceuticals, along with its US subsidiary Greenwich Biosciences, has launched EPIDIOLEX (cannabidiol) oral solution CV in the US for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in patients two years of age or older.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.